Email Alert | RSS    帮助

中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (12): 1243-1247.doi: 10.3969/j.issn.1000-6621.2021.12.004

• 专家笔谈 • 上一篇    下一篇


贺晓新*, 李波, 周林()   

  1. 100035 北京结核病控制研究所(贺晓新、李波);中国疾病预防控制中心结核病预防控制中心患者关怀部(周林)
  • 收稿日期:2021-08-11 出版日期:2021-12-10 发布日期:2021-12-01
  • 通信作者: 周林

Interpretation of Four-month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

HE Xiao-xin*, LI Bo, ZHOU Lin()   

  1. *Beijing Research Institute for Tuberculosis Control, Beijing 100035, China
  • Received:2021-08-11 Online:2021-12-10 Published:2021-12-01
  • Contact: ZHOU Lin



关键词: 利福喷丁, 莫西沙星, 临床方案, 药物疗法,联合, 评论, 基于问题的学习


In May 2021, the New England Journal of Medicine published a multi-center, open, randomized controlled non-inferiority phase Ⅲ clinical trial study of the Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. World Health Organization recommended this chemotherapy regimen to all of the world in June 2021. Upon review and analysis, the clinical trial study was with rigorous and reasonable research design,systematic and comprehensive quality control measures, and the research results were credible. The study results showed that the 4-month anti-tuberculosis chemotherapy regimen was not inferior to the 6-month standard chemotherapy regimen in terms of therapeutic effect, safety and tolerability. The dosage of rifapentine (1200 mg/d) in this regimen is 7-14 times of that recommended by Chinese Pharmacopoeia (600 mg per time for adults, 1-2 times per week). Usage of anti-tuberculosis drugs is one of the important cause of drug-induced liver damage in China. At present, a certain proportion of rifampicin in China does not reach the current recommended dose (600 mg/d), mainly due to medical staff’s concerns about liver injury. Combined with the comprehensive analysis of Chinese Pharmacopoeia regulations, national rifampicin use and influencing factors, this short-course regimen needs to be piloted before it is promoted and applied in China, and relevant professional guidance should be issued.

Key words: Rifapentine, Moxifloxacin, Clinical protocols, Drug therapy,combination, Comment, Problem-based learning